Information  X 
Enter a valid email address

Antisoma plc (SRC)

  Print      Mail a friend       Annual reports

Monday 09 June, 2008

Antisoma plc

Result of EGM





NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN
OR INTO THE UNITED  STATES, CANADA, AUSTRALIA OR  JAPAN OR ANY  OTHER
JURISDICTION WHERE  TO DO  SO  WOULD CONSTITUTE  A VIOLATION  OF  THE
RELEVANT LAWS OF SUCH JURISDICTION

Antisoma's acquisition of Xanthus Pharmaceuticals Inc. approved by
shareholders

Antisoma plc (LSE:ASM;  USOTC:ATSMY) announces  that the  resolutions
put to  today's Extraordinary  General  Meeting (EGM)  of  Antisoma's
shareholders were passed with the support of over 89% of votes  cast.
These included a resolution to acquire Xanthus Pharmaceuticals  Inc.,
and, by  association, the  fundraising linked  with the  acquisition.
Full details of the proxy voting are available on Antisoma's  website
at www.antisoma.com

Copies of the resolutions passed at the EGM today are available for
inspection at the UK Listing Authority's Document Viewing Facility,
which is situated at:

The Financial Services Authority
25 The North Colonnade
Canary Wharf
London E14 5HS
Tel: +44 (0) 20 7066 1000

A further announcement will be made regarding admission of the shares
issued in connection with the acquisition and fundraising and the
completion of the transaction.

Enquiries:


Antisoma plc                                     Tel: +44 (0)7909 915
                                                 068
Glyn Edwards, Chief Executive Officer
Daniel Elger, Director of Communications

Buchanan Communications                          Tel: +44 (0)20  7466
                                                 5000
Mark    Court/Lisa     Baderoon/Rebecca     Skye
Dietrich


Piper Jaffray Ltd                                Tel: +44 (0)20  3142
                                                 8700
Neil Mackison
Rupert Winckler


Background to the acquisition and fundraising
On 16 May, Antisoma announced that  it had entered into an  agreement
to acquire private US oncology company Xanthus Pharmaceuticals,  Inc.
in an all-share deal valued at  GBP 26.8 million  (USD 52.2  million)
and that  it had  simultaneously  executed a  fundraising  providing,
before expenses,  an  additional GBP  20.9  million to  the  Enlarged
Group. Further details are available in the press release of 16 May.

Notes and disclaimers
Piper Jaffray, which  is authorised and  regulated in the  UK by  the
Financial Services  Authority, is  acting  as financial  adviser  and
broker to Antisoma in connection  with the proposals and no-one  else
and will  not  be  responsible  to anyone  other  than  Antisoma  for
providing the protections  afforded to clients  of Piper Jaffray  nor
for providing  advice in  relation  to the  proposals nor  any  other
matter referred to in this announcement.

Words and expressions used in this announcement will have the same
meaning as defined in the prospectus and circular that has been sent
to shareholders.

This document does not constitute an offer or invitation to purchase
or subscribe for any securities of Antisoma and no part of it shall
form the basis of or be relied upon in connection with any contract
or commitment whatsoever.

The information contained herein is not for publication, distribution
or release in or into the United States.  The material set forth
herein is for informational purposes only and is not intended, and
should not be construed, as an offer of securities for sale in the
United States.  The securities described herein have not been and
will not be registered under the U.S. Securities Act of 1933, as
amended (the "Securities Act"), or the laws of any state or other
jurisdiction, and may not be offered or sold within the United
States, except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act and
applicable laws of any state or other jurisdiction.  There is no
intention to register any portion of the securities described herein
in the United States.

This document is not an offer to sell or the solicitation of an offer
to buy any securities in any jurisdiction where such offer or sale is
not permitted.

Certain matters discussed in this statement are forward looking
statements that are subject to a number of risks and uncertainties
that could cause actual results to differ materially from results,
performance or achievements expressed or implied by such statements.
These risks and uncertainties may be associated with product
discovery and development or licensing activities, including
statements regarding the clinical development programmes, the
expected timing of clinical trials and regulatory filings,
out-licensing opportunities, and funding requirements. Such
statements are based on management's current expectations, but actual
results may differ materially.

---END OF MESSAGE---